These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7470372)

  • 21. Displacement of phenytoin from plasma binding sites by salicylate.
    Fraser DG; Ludden TM; Evens RP; Sutherland EW
    Clin Pharmacol Ther; 1980 Feb; 27(2):165-9. PubMed ID: 7353334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro simulation of drug intestinal absorption.
    Lamberti G; Cascone S; Iannaccone M; Titomanlio G
    Int J Pharm; 2012 Dec; 439(1-2):165-8. PubMed ID: 23078860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic drug interactions with phenytoin (Part I).
    Nation RL; Evans AM; Milne RW
    Clin Pharmacokinet; 1990 Jan; 18(1):37-60. PubMed ID: 2178849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of capacity-limited systems.
    Jusko WJ
    J Clin Pharmacol; 1989 Jun; 29(6):488-93. PubMed ID: 2666450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.
    Verbeeck RK
    Clin Pharmacokinet; 1990 Jul; 19(1):44-66. PubMed ID: 2199127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenytoin-salicylate interaction.
    Leonard RF; Knott PJ; Rankin GO; Robinson DS; Melnick DE
    Clin Pharmacol Ther; 1981 Jan; 29(1):56-60. PubMed ID: 7460475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calculation of normalized drug concentrations in the presence of altered plasma protein binding.
    Musteata FM
    Clin Pharmacokinet; 2012 Jan; 51(1):55-68. PubMed ID: 22149258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variability in the human drug response.
    Sweeney GD
    Thromb Res Suppl; 1983; 4():3-15. PubMed ID: 6356464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intestinal absorption and renal excretion mediated by transporters and the relationship with drug-drug interaction].
    Zhang J; Liu KX
    Yao Xue Xue Bao; 2010 Sep; 45(9):1089-94. PubMed ID: 21351563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a).
    Usansky HH; Sinko PJ
    J Pharmacol Exp Ther; 2005 Jul; 314(1):391-9. PubMed ID: 15833900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption.
    Deng J; Jhandey A; Zhu X; Yang Z; Yik KFP; Zuo Z; Lam TN
    PLoS One; 2018; 13(8):e0203361. PubMed ID: 30169515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A package of computer programs designed to simulate pharmacokinetic monitoring of drug therapy.
    Sullivan TJ; Wunderley DJ
    Comput Programs Biomed; 1980 Dec; 12(2-3):85-95. PubMed ID: 7249607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of hepatic clearance with the account of drug-protein binding kinetics.
    Berezhkovskiy LM
    J Pharm Sci; 2012 Oct; 101(10):3936-45. PubMed ID: 22767378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of anticonvulsants.
    Hvidberg EF; Dam M
    Clin Pharmacokinet; 1976; 1(3):161-88. PubMed ID: 797496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic disease and drug pharmacokinetics.
    Williams RL; Mamelok RD
    Clin Pharmacokinet; 1980; 5(6):528-47. PubMed ID: 7002418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. General pharmacokinetic equations for linear mammillary models with drug absorption into peripheral compartments.
    Vaughan DP; Mallard DJ; Trainor A; Mitchard M
    Eur J Clin Pharmacol; 1975 Feb; 8(2):141-8. PubMed ID: 1233210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronopharmacokinetics. Current status.
    Bruguerolle B
    Clin Pharmacokinet; 1998 Aug; 35(2):83-94. PubMed ID: 9739478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipophilicity and biological acitivity. Drug transport and drug distribution in model systems and in biological systems.
    Kubinyi H
    Arzneimittelforschung; 1979; 29(8):1067-80. PubMed ID: 40579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.